Scientific Sessions 2024  /  Featured Science: Novel Approaches to Managing Lipid Risk  /  Discussant: PALISADE
Logo

American Heart Association

  158
  0

Final ID:

Discussant: PALISADE

  • Shapiro, Michael  ( Wake Forest Univ School of Medicine , Winston Salem , North Carolina , United States )
    • Author Disclosures:
    Michael Shapiro: DO have relevant financial relationships ; Consultant:Amgen:Active (exists now) ; Advisor:Arrowhead:Active (exists now) ; Advisor:Merck:Active (exists now) ; Consultant:Regeneron:Active (exists now) ; Advisor:Ionis:Active (exists now) ; Advisor:Agepha:Past (completed) ; Consultant:Novartis:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Novel Approaches to Managing Lipid Risk

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial

Kereiakes Dean, Fourie Nyda, Scott Russell, Asprusten Emil, Yalim Zafer, Vest Jeff, Kallend David, Stein Evan

Transcriptomic Signatures and Predictors of Evolocumab Added to Maximum Statin Therapy Based on Intra-Coronary Plaque Characteristics: YELLOW III Study

Kini Annapoorna, Krishnamoorthy Parasuram, Hooda Amit, Minatoguchi Shingo, Baruah Nimisha, Pineda Derek, Chen Vivian, Ellis Ethan, Hahn Aana, Krishnan Prakash, Moreno Pedro, Vengrenyuk Yuliya, Mehran Roxana, Sebra Robert, Zhou Xiaobo, Narula Jagat, Sharma Samin, Liu Jiajia, Yasumura Keisuke, Mandava Aishwaria, Shah Hardik, Sweeny Joseph, Khera Sahil, Kapur Vishal

More abstracts from these authors:
Opportunities to Implement Cardiometabolic Health Promotion in the Cardiac Cath Lab

Michos Erin, Shapiro Michael

Debate: Should Statins be Started in Young Individuals for Primary Prevention? (Pro)

Shapiro Michael, Bailey Alison

You have to be authorized to contact abstract author. Please, Login
Not Available